Morgan Stanley Reiterates Underweight on bluebird bio, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has reiterated an 'Underweight' rating on bluebird bio (NASDAQ:BLUE) and maintained a $3 price target.
July 11, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has reiterated an 'Underweight' rating on bluebird bio, maintaining a $3 price target.
The 'Underweight' rating from Morgan Stanley suggests that they expect bluebird bio's stock to underperform compared to other stocks in the market. This, coupled with the maintained low price target of $3, could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100